Format

Send to

Choose Destination
PLoS Med. 2016 Jun 14;13(6):e1002043. doi: 10.1371/journal.pmed.1002043. eCollection 2016 Jun.

Delinking Investment in Antibiotic Research and Development from Sales Revenues: The Challenges of Transforming a Promising Idea into Reality.

Author information

1
Boston University School of Law, Boston, Massachusetts, United States of America.
2
Chatham House Centre for Global Health Security, London, United Kingdom.
3
DRIVE-AB, Innovative Medicines Initiative, Geneva, Switzerland.
4
Oslo University Hospital, Oslo, Norway.
5
Norwegian Institute of Public Health, Oslo, Norway.
6
Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, United States of America.
7
ReAct - Action on Antibiotic Resistance, Uppsala, Sweden.
8
London School of Economics, London, United Kingdom.
9
University of Oslo, Oslo, Norway.
10
Harvard School of Public Health, Boston, Massachusetts, United States of America.

Abstract

Kevin Outterson and colleagues outline a model to address access, conservation, and innovation of antibiotics.

PMID:
27299990
PMCID:
PMC4907461
DOI:
10.1371/journal.pmed.1002043
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Public Library of Science Icon for PubMed Central
Loading ...
Support Center